Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
Condition: Lymphoma; Unspecified Adult Solid Tumor, Protocol Specific
MeSH terms: Lymphoma
Intervention: ridaforolimus; vorinostat; biopsy; pharmacological study; laboratory biomarker analysis
Intervention description: Given PO; Given PO; Optional correlative studies; Correlative studies; Correlative studies
Intervention MeSH terms: Vorinostat
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 16.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This phase I trial is studying the side effects and best dose of giving ridaforolimus and
      vorinostat together in treating patients with advanced solid tumors or lymphoma. Giving
      ridaforolimus in combination with vorinostat may stop the growth of cancer cells by blocking
      some of the enzymes needed for cell growth.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological confirmation of a solid, malignant tumor or lymphoma that
             is refractory to standard therapies or for which no standard therapies exist

          -  Patients must have received at least one prior systemic therapy

          -  Measureable disease by RECIST v 1.1

          -  ECOG PS 0 or 1

          -  ANC >= 1500/uL

          -  Hgb >= 9 g/dL

          -  Platelets >= 100,000/uL

          -  AST/SGOT and ALT/SGPT =< 2.5 x upper limit of normal (ULN) or =< 5.0 x ULN in patients
             with liver metastases

          -  Total Bilirubin =< 1.5 times ULN

          -  Creatinine =< 2.0 mg/dL or Creatinine Clearance (calculated or 24 hour urine) >= 50
             ml/min

          -  Female patients of childbearing potential must have a negative serum or urine
             pregnancy test =< 21 days of study enrollment and agree to use an effective method of
             contraception for the duration of the study

          -  Ability to understand and willingness to sign written informed consent

        Exclusion Criteria:

          -  Prior anti-cancer treatment with either an mTOR inhibitor (i.e. temsirolimus,
             everolimus), or an HDAC inhibitor (i.e. Vorinostat)

          -  Patients who have received bevacizumab =< 6 weeks prior to day 1 of study treatment;
             patients who have received other chemotherapy, immunotherapy, or radiotherapy =< 3
             weeks prior to day 1 of study treatment or those who have not recovered from acute
             adverse events due to agents administered >= 3 weeks earlier; for patients receiving
             targeted therapy, treatment must be discontinued at least five half-lives prior to
             initiation of day 1 of study treatment

          -  Patients who have taken valproic acid =< 2 weeks of study enrollment; valproic acid is
             another HDAC inhibitor

          -  Patients who are pregnant, plan to become pregnant, or are breastfeeding

          -  History of gastrointestinal bleeding within1 month of enrollment

          -  Serum cholesterol >= 350 mg/dL or serum triglycerides >= 400 mg/d

          -  Poorly controlled Type 1 or 2 diabetes, defined as hemoglobin A1C greater than 8% or a
             fasting glucose of > 160 mg/dL

          -  Active infection requiring antibiotics

          -  Anaphylactic reaction to macrolide antibiotics, Tween 80 (polysorbate 80)

          -  Patients who are not adequately recovered from a prior surgical procedure or major
             surgical procedure within 2 weeks prior to the first dose of study drug

          -  Myocardial infarction of unstable angina within 3 months of study entry

          -  NY Heart Association class III or IV congestive heart failure

          -  Known active parenchymal brain metastases; patients who have had brain metastases
             resected, or have received radiation therapy ending > 4 weeks prior to study entry are
             eligible if they meet all of the following criteria: 1) residual neurologic symptoms <
             grade 1, 2) no steroid requirement, 3) a follow-up MRI shows regression or stability
             of lesions after treatment, with no new lesions appearing

          -  Unable to swallow whole pills

          -  A requirement for one of the prohibited medications; if patient is currently taking
             one of these medications, they may be eligible so long as they discontinue the
             prohibited medication prior to starting study treatment and remain off for the
             duration they are taking study treatment

          -  Known diagnosis of HIV

          -  Concurrent malignancies are excluded with the following exceptions: basal cell skin
             cancer is allowed; cervical carcinoma in situ is allowed; any malignancy that does not
             require active treatment, and from which the patient has been disease free for >= 3
             years is allowed